Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company.

Several research analysts have recently issued reports on ZLDPF shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Finally, BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th.

Zealand Pharma A/S Stock Performance

ZLDPF opened at $44.71 on Thursday. The company has a market cap of $3.18 billion, a P/E ratio of 3.27 and a beta of 0.88. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $54.91 and its 200-day moving average is $67.45. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53. The business had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. Equities research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.